Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission
Maternal Nucleos(t)Ide Analogue Use and Infants Immunoprophylaxis to Eliminate Hepatitis B Infection in the Real World Setting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215400
- The First People's Hospital of Taicang
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- HBsAg positive women who were less than 28 weeks pregnant and underwent routine testing for HBV at the Department of Infectious Diseases of Taicang First People's Hospital at least twice during pregnancy
Exclusion Criteria:
- women treated with antiviral drugs during pregnancy.
- drug hypersensitivity;
- abnormal renal laboratory results;
- coinfection with human immunodeficiency virus or other human hepatitis viruses.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
The treatment group
Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
|
Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
|
|
The control group with high HBV DNA level
Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
|
|
|
The control group with low HBV DNA level
Pregnant women with high HBV DNA level < 2*10^6 IU/ml
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of children who developed chronic HBV infection between the treatment group and two control groups in the real-world setting.
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups in the real life setting
|
December, 2018
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the proportion of children who developed chronic HBV infection between the treatment group and two control groups among infants who followed the standardized immunoprophylaxis strategy
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups who followed the standardized immunoprophylaxis strategy
|
December, 2018
|
|
the proportion of children who developed chronic HBV infection between the treatment group and two control groups among infants who followed the aggressive immunoprophylaxis strategy
Time Frame: December, 2018
|
We compare the proportion of children with chronic HBV born to mothers from three groups who followed the aggressive immunoprophylaxis strategy
|
December, 2018
|
|
The proportion of children with detectable HBV DNA and HBsAg in umbilical cord blood
Time Frame: At delivery
|
We compare the proportion of children with detectable HBV DNA and HBsAg in umbilical cord blood born to mothers from three groups
|
At delivery
|
|
The HBV DNA level of mothers among three groups
Time Frame: Within one week before delivery.
|
We compare the HBV DNA level of mothers among three groups within one week before delivery.
|
Within one week before delivery.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yonglan Pu, The First People's Hospital of Taicang
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RWD-0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.